Galecto Biotech welcomes new COO

Copenhagen, April 2, 2013

Galecto Biotech AB announces today the appointment of Anders Pedersen who joins the recently founded biotech company as Chief Operating Officer. Anders Pedersen will be responsible for managing Galecto Biotech’s project portfolio and will be focusing on building exclusive collaborations and partnerships with its service providers.

Anders Pedersen offers more than 25 years of experience in the biopharmaceutical industry and significant expertise in process development and discovery of biopharmaceuticals. Previously, Anders Pedersen served as Senior Vice President of Development at CMC Biologics and prior to this position he spent 13 years at Novo Nordisk. He was a cofounder of ProFound Pharma, which was later acquired by Maxygen, and furthermore served as Vice President of Project and Portfolio Management at Life Cycle Pharma and as Chief Operating Officer at Recepticon. Anders Pedersen holds a degree in Chemical Engineering from the Technical University of Denmark.

“We are very pleased to welcome Anders on board”, says Dr. Hans Schambye, CEO of Galecto Biotech. “Strengthening our organization with a highly skilled COO such as Anders who brings a profound understanding of the pharmaceutical area, will contribute to accelerate development of our key drug candidates, – ultimately by bringing these to demonstration of clinical effect”.

About Galecto Biotech AB
Galecto Biotech is a newly founded company, focused on developing novel drugs for the treatment of fibrosis, inflammation and other serious human diseases. The company’s products target galectins or galactoside binding lectins, which are a group of proteins shown to be involved in many disease processes. Galecto Biotech’s high potency galectin inhibitors may open new treatment possibilities for many patients. The company is led by top-level scientists and biotech executives. Galecto Biotech is located in Copenhagen, Denmark, in close proximity to the founders’ research groups.
For more information, visit

For further information please contact:
Hans Schambye
CEO, Galecto Biotech
Tel: +45 26 3737 26

Cookies Privacy Policy